On July 27, 2012, Galderma Laboratories filed a lawsuit (available here) in the Northern District of Texas against Watson Pharmaceuticals. Galderma claims that Watson submitted an ANDA (abbreviated new drug application) seeking approval to engage in the commercial manufacture, use, and sale of generic Adapalene and Benzoyl Peroxide Gel. Galderma claims that this product infringes the claims of three of its patents. Galderma seeks, among other things, damages and injunctive relief.
Galderma is represented by Michael Wilson, Jamil Alibhai, and Daniel Venglarik, all of Munck Wilson Mandala, LLP; and Aaron Fountain, Stuart Pollack, and Jeffrey Johnson, all of DLA Piper LLP.